ONC_LIGHT D0816L00003

Non-Randomized, Open-Label Phase II Study to Assess Olaparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That Have Received at Least 2 Prior Lines of Chemotherapy

Phase II
NCT02983799
Cancer, All Other
Gynecologic
Melissa Hardesty MD
AstraZeneca
Susan Wildman
  • Alaska Research
  • Alaska Women's Cancer Care